BioStack Raises $9.5M | Ayble Health Raises $16M Series A

Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.

BioStack Raises $9.5M to Turn Global Hospital Data into Multimodal Training Datasets for Medical AI

Y Combinator Startup Transforms 100 Million Fragmented Patient Records Into Multimodal Training Data and Reinforcement Learning Environments for Medical AI Agents

BioStack, a healthcare technology company, announced today that it’s launching a data infrastructure network to power the next era of medicine. It spans a global footprint across the U.S., India, Brazil, and Argentina with over 100 million de-identified patient records. By connecting fragmented clinical information, BioStack gives AI and biotech companies the high-quality data needed to train models that understand how disease unfolds, how treatments work, and what drives patient outcomes.

The company also announced $9.5 million in seed funding led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures, and Y Combinator. The round will support BioStack’s continued expansion across the United States and international markets, development of its technology platform, and growth of its engineering and research teams.

Today, patient histories and other clinical data are often fragmented across hospitals, providers, and technology systems, leaving clinicians without a complete picture of a patient’s treatment. BioStack creates workflows that bring together clinical information across disparate health systems and geographies. Connecting notes, labs, imaging, medications, treatments, and outcomes, BioStack provides a more comprehensive view of the patient and informs population-level and hospital-level discovery.

“Collecting every event linked to each patient enables a view of what happens at each stage of a patient’s journey,” said Sanat Mishra, Co-Founder and CEO at BioStack…

Full release here, originally announced October 22nd, 2026.

Ayble Health Raises $16M Series A to Expand the Nation’s Most Clinically Validated Virtual Digestive Health Clinic

Led by Neon, the Oversubscribed-Round Accelerates Expansion Into AI Precision Digestive Healthcare and Autoimmune Health, Driven by Rapid Scaling Across National Health Plans, Jumbo Employers, and Major Benefit Platforms

Ayble Health, the nation’s leading AI-enabled virtual multidisciplinary GI clinic, today announced the close of a $16 million oversubscribed Series A round led by Neon, with participation from Unum Ventures, Upfront Ventures, M13, Cleveland Clinic Ventures, DigiTx, Accomplice, and several individual strategic investors. The round brings Ayble’s total capital raised to over $27 million.

Undertreated, Underserved, and Enormously Costly

Digestive and autoimmune conditions are among the most common, costly, and under-addressed chronic diseases in the country. GI conditions alone affect more than 70 million Americans and drive $136 billion in annual U.S. healthcare spending, more than the total cost of diabetes or heart disease, while nearly 70% of U.S. counties lack a single practicing gastroenterologist. The two categories are also clinically intertwined: a 2025 study spanning more than 141 million patients found inflammatory bowel disease (IBD) associated with 24 distinct autoimmune comorbidities, underscoring the need for a care model built to treat patients across both conditions.

Meeting this dual burden requires a care model that can adapt to each patient’s overlapping conditions rather than treating them in isolation. This new capital will be used to advance Ayble’s proprietary AI+clinician precision care model, deepening data-driven personalization for patient engagement, enrollment, and care delivery. Additionally, the company will leverage its proven multidisciplinary model and data infrastructure to expand beyond its core gastrointestinal (GI) footprint into adjacent complex therapeutic areas, starting with autoimmune conditions…

Full release here, originally announced September 17th, 2026.